Alta Wealth Advisors LLC Has $277,000 Stake in BioMarin Pharmaceutical Inc. $BMRN

Alta Wealth Advisors LLC decreased its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 32.2% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 5,044 shares of the biotechnology company’s stock after selling 2,394 shares during the period. Alta Wealth Advisors LLC’s holdings in BioMarin Pharmaceutical were worth $277,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in BMRN. V Square Quantitative Management LLC acquired a new position in BioMarin Pharmaceutical in the 2nd quarter worth approximately $25,000. Farther Finance Advisors LLC boosted its stake in BioMarin Pharmaceutical by 95.9% in the 1st quarter. Farther Finance Advisors LLC now owns 431 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 211 shares during the period. Rise Advisors LLC acquired a new position in BioMarin Pharmaceutical in the 1st quarter worth approximately $30,000. Brooklyn Investment Group boosted its stake in BioMarin Pharmaceutical by 2,250.0% in the 1st quarter. Brooklyn Investment Group now owns 564 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 540 shares during the period. Finally, Banque Transatlantique SA acquired a new position in BioMarin Pharmaceutical in the 1st quarter worth approximately $71,000. Institutional investors and hedge funds own 98.71% of the company’s stock.

BioMarin Pharmaceutical Price Performance

Shares of BioMarin Pharmaceutical stock opened at $55.43 on Friday. The company has a current ratio of 5.56, a quick ratio of 3.60 and a debt-to-equity ratio of 0.10. The stock has a market capitalization of $10.64 billion, a price-to-earnings ratio of 16.45, a P/E/G ratio of 0.71 and a beta of 0.33. BioMarin Pharmaceutical Inc. has a 1-year low of $52.47 and a 1-year high of $73.51. The firm’s 50-day moving average price is $56.77 and its two-hundred day moving average price is $58.70.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on BMRN shares. Zacks Research lowered shares of BioMarin Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 13th. Weiss Ratings reissued a “sell (d+)” rating on shares of BioMarin Pharmaceutical in a research note on Saturday, September 27th. Wall Street Zen raised shares of BioMarin Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 13th. UBS Group lifted their target price on shares of BioMarin Pharmaceutical from $113.00 to $114.00 and gave the company a “buy” rating in a research note on Tuesday, August 5th. Finally, Guggenheim lifted their target price on shares of BioMarin Pharmaceutical from $101.00 to $106.00 and gave the company a “buy” rating in a research note on Wednesday, August 6th. Thirteen research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, BioMarin Pharmaceutical has a consensus rating of “Moderate Buy” and a consensus price target of $92.95.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.